Stock Price
109.10
Daily Change
-6.52 -5.64%
Monthly
-23.59%
Yearly
60.16%
Q2 Forecast
99.25

Insmed reported $1.61B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Cytokinetics USD 839.46M 77.51M Mar/2026
DBV Technologies USD 212.94M 124.06M Dec/2025
Gilead Sciences USD 18.64B 1.25B Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Novartis USD 30.46B 2.26B Dec/2025
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026